Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/s10434-006-9128-3
Annals of Surgical Oncology 14:211-217 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloomston, M.
Right arrow Articles by Frankel, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloomston, M.
Right arrow Articles by Frankel, W. L.

Original Article

Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer

Mark Bloomston, MD1, E. Christopher Ellison, MD1, Peter Muscarella, MD1, Osama Al-Saif, MBBS1, Edward W. Martin, MD1, W. Scott Melvin, MD1 and Wendy L. Frankel, MD2

1 Department of Surgery, Ohio State University, N924 Doan Hall, 410 W. 10th Ave., Columbus, OH 43210, USA
2 Department of Pathology, Ohio State University, 129 Hamilton Hall, 1645 Neil Ave., Columbus, OH 43210, USA

Correspondence: Address correspondence and reprint requests to: Mark Bloomston, MD; E-mail: mark.bloomston{at}osumc.edu

Background: Osteonectin has been suggested to be important in the progression of pancreatic cancer but has not been correlated with survival. We determined the osteonectin expression and its influence on survival in patients with ampullary carcinoma.

Methods: Tissue microarrays were constructed from the tumors of 56 patients with ampullary cancer undergoing pancreaticoduodenectomy. Immunohistochemical staining for osteonectin was undertaken and compared with staining in chronic pancreatitis (n = 13) and normal pancreas (n = 19). Survival curves were created by the Kaplan-Meier method and compared by log rank analysis. Median follow-up for all living patients with ampullary cancer was 69.6 months.

Results: Osteonectin was significantly (P < .05, Fisher’s exact test) overexpressed in the stroma of ampullary cancers (90%) relative to chronic pancreatitis (62%) and normal pancreas (0%). Tumors expressing osteonectin were more likely to have nodal metastases than those lacking osteonectin expression (48% vs. 0%, P = .06, Fisher’s exact test) and showed decreased survival. Node-negative status, pylorus preservation at the time of pancreaticoduodenectomy, and lack of osteonectin expression were predictors of prolonged survival by multivariate analysis.

Conclusions: Although the importance of tumor-stroma interactions in periampullary cancers is not fully understood, our data suggest that osteonectin is an integral stromal element in ampullary cancers, and its overexpression is associated with decreased survival.

Key Words: Ampulla of Vater • Ampullary cancer • Osteonectin • Osteopontin • Tissue microarray • Survival







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.